Degree of Decrease in Central Retinal Thickness Predicts Visual Acuity Response to Intravitreal Ranibizumab in Diabetic Macular Edema

Santos, Ana Rita; Gomes, Sara C.; Figueira, João; Nunes, Sandrina; Lobo, Conceição; Cunha-Vaz, Josè

doi:10.1159/000355487

Cited by 20 publications

(20 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although improvements in VA were not statistically significant at the 4- or 6-month visit, VA did improve as CST decreased among our patients. Santos et al [ 32 ] also reported correlations between decreased CST and improved VA. Long-standing DME that does not respond to treatment might lead to photoreceptor damage and visual impairment [ 33 ]. Therefore, preventing long-standing DME is important for avoiding severe visual loss.…”

Section: Discussionmentioning

confidence: 96%

Effect of Posterior Subtenon Triamcinolone Acetonide Injection on Diabetic Macular Edema Refractory to Intravitreal Bevacizumab Injection

Kim

Moon

Yang

et al. 2016

Korean J Ophthalmol

View full text Add to dashboard Cite

PurposeTo evaluate the effects of posterior subtenon triamcinolone acetonide injection on refractory diabetic macular edema (DME) after intravitreal bevacizumab (IVB) injection failure.MethodsPatients with DME and central subfield thickness (CST) >300 µm who did not respond to IVB injections were retrospectively included. Specifically, we enrolled patients who were diagnosed with refractory DME and who experienced an increase in CST after 1 to 2 IVB injections or no decrease after ≥3 consecutive IVB injections. One clinician injected 20 mg of triamcinolone acetonide into the posterior subtenon space. All patients received ophthalmic examinations at baseline and at 2, 4, and 6 months post-baseline. Examinations included Snellen visual acuity, intraocular pressure, and spectral-domain optical coherence tomography.ResultsForty eyes of 34 patients were included. The average baseline CST was 476 µm. The average CST decreased to 368 µm at 2 months, 374 µm at 4 months, and 427 µm at 6 months (p < 0.001 for all results, Wilcoxon signed-rank test). The average intraocular pressure increased from 15.50 to 16.92 mmHg at 2 months but decreased to 16.30 mmHg at 4 months and 15.65 mmHg at 6 months. Logarithm of the minimum angle of resolution visual acuity improved from 0.56 to 0.50 at 2 months (p = 0.023), 0.50 at 4 months (p = 0.083), and 0.48 at 6 months (p = 0.133, Wilcoxon signed-rank test). No complications were detected.ConclusionsPosterior subtenon triamcinolone acetonide is an effective and safe treatment for reducing CST in DME refractory to IVB.

show abstract

Section: Discussionmentioning

confidence: 96%

Effect of Posterior Subtenon Triamcinolone Acetonide Injection on Diabetic Macular Edema Refractory to Intravitreal Bevacizumab Injection

Kim

Moon

Yang

et al. 2016

Korean J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Spectral-domain OCT is a commonly used commercial objective method for measuring retinal thickness, particularly CMT [25]. CMT is significantly correlated with VA in preterm children [32] or pediatric patients with diagnosed retinal diseases [33].…”

Section: Discussionmentioning

confidence: 99%

“…We used spectral-domain OCT (iTVue SD-OCT; Optovue Inc. Fremont, CA, U.S.A.) to evaluate the bilateral central macular thickness (CMT) of the included children with unilateral congenital cataract at 3 months after surgery [24, 25]. The macula was divided into three concentric circles with radii of 1, 3 and 6 mm, separately.…”

Section: Methodsmentioning

confidence: 99%

Interocular anatomical and visual functional differences in pediatric patients with unilateral cataracts

Long¹,

Chen²,

Liu³

et al. 2016

BMC Ophthalmol

View full text Add to dashboard Cite

BackgroundCongenital cataracts are often complicated by anterior segment dysgenesis. This study aims to compare bilateral anterior segment parameters, macular thickness, and best-corrected visual acuity (BCVA) in pediatric cataract patients at 3 months after unilateral cataract extraction with intraocular lens implantation.MethodsFifty-three pediatric patients with uncomplicated unilateral total cataracts were included. At 3 months post-surgery, bilateral corneal thickness at the thinnest location (CTTL), anterior chamber depth (ACD), and anterior chamber volume (ACV) were measured using Pentacam. Central macular thickness (CMT) was evaluated using spectral-domain optical coherence tomography. BCVA was measured by experienced optometrists concurrently. Descriptive statistics and bivariate corrections were performed to analyze the interocular differences in bilateral anatomic parameters and their relationships with BCVA.ResultsFor all 53 included patients (mean age 5.2 ± 2.3 years), the median BCVA was 10/40 in the operated eyes and 40/40 in the contralateral eyes, which indicates a significant interocular difference. BCVA values in the contralateral eyes were significantly correlated with patient age at surgery, but this result differed for BCVA in the operated eyes. The Pentacam analysis revealed no significant interocular differences in bilateral CTTL and ACV, but significant differences were found for ACD.ConclusionsAt 3 months after surgery, unilateral pediatric cataract patients exhibited no significant interocular differences in identified anatomical parameters (except for ACD), and these parameters were not significantly correlated with BCVA in bilateral eyes. Therefore, amblyopia, but not anatomical factors, might be the main cause of interocular visual functional differences in our study population.Trial registrationClinicalTrial.gov, NCT02765230, 05/05/2016, retrospectively registered.Electronic supplementary materialThe online version of this article (doi:10.1186/s12886-016-0371-5) contains supplementary material, which is available to authorized users.

show abstract

“…They found that BCVA improved from 4.78 and 5.52 letters, and a central retinal thickness decreased from 80.25 and 106.12 microns after 3 and 6 months of treatment. They concluded that optimal responders to anti-VEGF therapy could be identified based on their response to decrease in central retinal thickness and hence, could be a predictor of BCVA improvement after the treatment 16 .…”

Section: Discussionmentioning

confidence: 99%

Change in Visual Acuity in Relation to Central Macular Thickness after Intravitreal Bevacizumab in Diabetic Macular Edema

Haider¹,

Sattar

Zaidi³

2020

pak J Ophthalmol

View full text Add to dashboard Cite

Purpose: To evaluate the change in visual acuity in relation to decrease in central macular thickness,after a single dose of intravitreal Bevacizumab injection.Study Design: Quasi experimental study.Place and Duration of Study: Punjab Rangers Teaching Hospital, Lahore, from January 2019 to June 2019.Material and Methods: 70 eyes with diabetic macular edema were included in the study. Patients having high refractive errors (spherical equivalent of > ± 7.5D) and visual acuity worse than +1.2 or better than +0.2 on log MAR were excluded. Central macular edema was measured in μm on OCT and visual acuity was documentedusing Log MAR chart. These values were documented before and at 01 month after injection with intravitrealBevacizumab. Wilcoxon Signed rank test was used to evaluate the difference in VA beforeand after the anti-VEGF injection. Difference in visual acuity and macular edema (central) was observed,analyzed and represented in p value. P value was considered statistically significant if it was less than 0.01%.Results: Mean age of patients was 52.61 ± 1.3. Vision improved from 0.90 ± 0.02 to 0.84 ± 0.02 on log MARchart. The change was statistically significant with p value < 0.001. Central macular thickness reduced from 328 ±14 to 283 ± 10.6 μm on OCT after intravitreal anti-VEGF, with significant p value < 0.001.Conclusion: A 45 μm reduction in central macular thickness was associated with 0.1 Log MAR unit improvementin visual acuity after intravitreal Bevacizumab in diabetic macular edema.

show abstract

Degree of Decrease in Central Retinal Thickness Predicts Visual Acuity Response to Intravitreal Ranibizumab in Diabetic Macular Edema

Cited by 20 publications

References 33 publications

Effect of Posterior Subtenon Triamcinolone Acetonide Injection on Diabetic Macular Edema Refractory to Intravitreal Bevacizumab Injection

Effect of Posterior Subtenon Triamcinolone Acetonide Injection on Diabetic Macular Edema Refractory to Intravitreal Bevacizumab Injection

Interocular anatomical and visual functional differences in pediatric patients with unilateral cataracts

Change in Visual Acuity in Relation to Central Macular Thickness after Intravitreal Bevacizumab in Diabetic Macular Edema

Contact Info

Product

Resources

About